Homocysteine Optimal Level: What Your Number Means — and the Honest B-Vitamin Story

An optimal homocysteine is below 8 µmol/L by the functional-medicine playbook, while standard labs call anything below 15 µmol/L normal — and the honest position is that the 8 cutoff is an extrapolation from observational data, not a proven treatment target. What the data actually show: in the Homocysteine Studies Collaboration meta-analysis of prospective studies, each 25 percent lower homocysteine (about 3 µmol/L) was associated with 11 percent lower ischemic heart disease risk and 19 percent lower stroke risk — a continuous gradient with no threshold where risk switches on. 15–30 µmol/L is a moderate elevation that almost always has a findable cause, 30–100 is high and needs a medical workup, and above 100 is the territory of classical homocystinuria, a genetic disease — not a biohacking project.

Homocysteine is reported in µmol/L almost everywhere. If you ever see mg/L, multiply by 7.4 to get µmol/L (1 µmol/L = 0.135 mg/L). Test fasting, and note that sample handling matters — blood left sitting unprocessed reads falsely high.

My homocysteine is 12 — should I worry?

A homocysteine of 12 µmol/L is lab-normal and above optimal. In observational terms, someone at 12 carries a modestly higher associated risk than someone at 8 — using the Homocysteine Studies Collaboration gradient, roughly 10–15 percent higher ischemic heart disease risk and around 20 percent higher stroke risk for that ~4 µmol/L gap. Those are associations, not proof your arteries are in trouble: the randomized trials below are exactly why a 12 should not scare you.

What a 12 is genuinely useful for is as a prompt. Mild elevations most often trace back to low B12 or folate status, and homocysteine rises early — often before serum B12 looks clearly abnormal — which makes it a decent functional check on your B-vitamin status. So the rational response to a 12 is: check B12 and folate, check kidney function and thyroid on your next panel, look at the risk factors that are proven causal — ApoB, blood pressure, smoking, fasting insulin — and optionally run the cheap B-vitamin fix described below. Worry is not on the list.

Do B vitamins lower homocysteine — and does that actually prevent anything?

Here is the part most supplement content omits. B vitamins lower homocysteine reliably and substantially: in the Homocysteine Lowering Trialists’ dose-response meta-analysis, folic acid 0.8 mg/day cut homocysteine by about 23 percent, with vitamin B12 adding roughly 7 percent more. The lowering works. The problem is what happened when huge trials tested whether that lowering prevents cardiovascular events:

• HOPE-2 (5,522 people with vascular disease or diabetes, 5 years of folic acid 2.5 mg + B6 50 mg + B12 1 mg): homocysteine fell, but the primary outcome — cardiovascular death, heart attack, stroke — did not improve (relative risk 0.95, not significant).
• NORVIT (3,749 heart-attack survivors): homocysteine fell 27 percent, events did not fall — and the arm combining folic acid, B6 and B12 showed a trend toward harm (relative risk 1.22, 95% CI 1.00–1.50). The authors explicitly warned against this cocktail after myocardial infarction.
• VITATOPS (8,164 recent stroke/TIA patients): the composite outcome just missed significance (RR 0.91, p=0.05) — at best a modest effect.
• Cochrane 2017 (15 trials, ~71,000 participants): no effect on heart attack or death; a small reduction in stroke (RR 0.90, 95% CI 0.82–0.99).

The most coherent reading: homocysteine behaves mostly as a marker of underlying problems — B12/folate deficiency, kidney dysfunction, metabolic stress — rather than a direct cause of heart attacks. Lowering the number without fixing anything else is repainting the warning light. The one consistent exception is stroke in populations with poor folate status: in China, where food is not folate-fortified, the 20,702-person CSPPT trial found folic acid 0.8 mg/day reduced first stroke by 21 percent (2.7% vs 3.4%). If your diet is genuinely folate-poor, fixing that plausibly matters; if you eat fortified food and greens, expect less.

What about MTHFR?

MTHFR C677T is the most over-marketed gene variant on the internet, and the boring facts are these. Carrying one copy (CT) is extremely common — roughly 40 percent of many populations — and being TT (two copies) affects around 10 percent, more in Mediterranean and Hispanic populations. TT raises homocysteine by roughly 20–25 percent on average, and mostly when folate or riboflavin status is low; with good folate intake the genotypes largely converge. It is a modest dial, not a broken pathway.

The American College of Medical Genetics states it plainly: there is a lack of evidence justifying MTHFR testing at all, because the result does not change management. If you already know you are TT from a consumer DNA kit, two evidence-backed notes: first, riboflavin (vitamin B2) at just 1.6 mg/day lowered homocysteine by 22 percent in TT individuals — and did nothing in other genotypes — because riboflavin is the MTHFR enzyme’s cofactor. Second, methylfolate is a reasonable, cheap alternative to folic acid if you prefer to bypass the enzyme, but standard folic acid also works in TT carriers in the dose-response trials. What the evidence does not support: expensive “MTHFR protocols”, avoiding folic acid as if it were toxic, or treating the variant as a diagnosis. Measure homocysteine — the downstream output — instead of arguing about the gene.

Who should actually test homocysteine?

Homocysteine earns its place on a panel mainly as a functional B12 check for people at real risk of deficiency:

• Vegans and near-vegans — B12 comes almost entirely from animal foods; homocysteine rises when tissue B12 runs low, often before serum B12 flags.
• Metformin users — in a 4.3-year randomized trial, metformin reduced vitamin B12 by 19 percent and raised homocysteine; the authors recommended regular B12 monitoring, which most users never get.
• Adults over ~60 — B12 absorption declines with age as stomach acid and intrinsic factor output fall; long-term acid-suppressing drugs (PPIs) plausibly add to this.
• Anyone with unexplained fatigue, neuropathy or cognitive complaints plus a plant-heavy diet — as part of a proper B12 workup, with a clinician.
• Kidney impairment and a personal or strong family history of early blood clots — elevations here need medical interpretation, not supplements first.

For everyone else it is an optional, cheap (~10–30 EUR/USD) annual add-on: informative as a trend, not a number to obsess over. If you do track it, log each result in BioTrakk by chat along with your B-vitamin intake, so the before/after around any change is recorded instead of remembered.

How do you lower homocysteine — and why bother if the trials failed?

The protocol is unusually well quantified, cheap and safe at these doses:

• Folic acid 0.4–0.8 mg/day — 0.8 mg achieves near-maximal lowering (~23 percent); 0.4 mg gets ~20 percent. Food folate from legumes and leafy greens counts toward the same effect.
• Vitamin B12 0.4–1 mg/day orally — adds ~7 percent lowering on average, and is the actual fix whenever low B12 is the cause; high oral doses work even with poor absorption.
• Riboflavin 1.6 mg/day if you are MTHFR 677TT — the 22 percent genotype-specific effect cited above; pointless for other genotypes.
• Vitamin B6 — included in the classic trial cocktails, but it adds little to fasting homocysteine in the dose-response data; skip megadoses, which carry neuropathy risk over time.

Why bother, given HOPE-2 and NORVIT? Four honest reasons. First, an elevated homocysteine often means B12 or folate deficiency, and deficiency damages nerves, blood and brain regardless of what homocysteine does to arteries — fixing it is not optional. Second, the brain signal is genuinely interesting: in the VITACOG randomized trial, B vitamins slowed brain atrophy by about 30 percent over two years in older adults with mild cognitive impairment, with the largest effect in those starting above ~13 µmol/L — promising, not proof of dementia prevention. Third, the small stroke reduction in the Cochrane analysis and the CSPPT result mean the cardiovascular story is not entirely dead, especially with poor folate status. Fourth, the intervention costs cents and carries near-zero risk at these doses. What you should not expect — because the best trials looked hard and did not find it — is heart-attack protection.

This is also a textbook case for self-experimentation done honestly: a 12-week n-of-1 experiment — baseline draw, one intervention, retest — will show you your personal response size, and BioTrakk’s report will tell you plainly if the change beats measurement noise.

How often should you retest homocysteine?

Homocysteine responds to B vitamins within weeks and reaches a stable new level by about 6–12 weeks, so retest 8–12 weeks after starting an intervention — earlier retests waste money. After that, once a year is plenty for maintenance, ideally bundled with the rest of your annual bloodwork. Three practical rules: always test fasting, use the same laboratory so results are comparable, and treat any single surprising value as a prompt to repeat, not a verdict — biological plus preanalytical variation on this marker is real. A two-point trend beats any single number; a three-point trend beats an opinion.